Document is current
Any future updates will be listed below
-
Authors
Bourron, Olivier http://orcid.org/0000-0001-7348-7161
Phan, Franck
Diallo, Mamadou Hassimiou
Hajage, David
Aubert, Carole-Elodie
Carlier, Aurélie
Salem, Joe-Elie
Funck-Brentano, Christian
Kemel, Salim
Cluzel, Philippe
Redheuil, Alban
Davaine, Jean-Michel
Massy, Ziad
Mentaverri, Romuald
Bonnefont-Rousselot, Dominique
Gillery, Philippe
Jaisson, Stéphane
Vermeer, Cees
Lacorte, Jean-Marc
Bouziri, Nesrine
Laroche, Suzanne
Amouyal, Chloé
Hartemann, Agnes
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02431234 at ClinicalTrials.govDocuments that mention this clinical trial
Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy
https://doi.org/10.1186/s13098-019-0429-7
Circulating Receptor Activator of Nuclear Factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study
https://doi.org/10.1186/s12933-020-01122-4
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts
https://doi.org/10.1186/s12933-024-02161-x
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
Université de Lausanne
Ministère des Affaires Sociales et de la Santé
- License Information
-
More Information
Article History
Received: 17 May 2020
Accepted: 12 September 2020
First Online: 18 September 2020
Ethics approval and consent to participate
: The study was approved by the local ethics committee (PARIS VI CPP) and registered in ClinicalTrials.gov (Identifier: NCT02431234). All patients were informed about the study objectives and procedure. Participants gave their written informed consent to participation prior to inclusion.
: Not applicable.
: No conflict of interest in the area of this study. DIACART study was supported by a fund from the Lilly Company. The company was neither involved in the design of the study nor in data collection.
